Cargando…
Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma
Docetaxel has shown remarkable radiosensitizing in vitro properties. In a previous phase I/II dose escalation study in non- small-cell lung cancer (NSCLC) we observed a high response rate after concomitant boost radiotherapy and weekly docetaxel. The maximum tolerated dose was 30 mg m(−2) week(−1)....
Autores principales: | Koukourakis, M I, Bahlitzanakis, N, Froudarakis, M, Giatromanolaki, A, Georgoulias, V, Koumiotaki, S, Christodoulou, M, Kyrias, G, Skarlatos, J, Kostantelos, J, Beroukas, K |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1999
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363119/ https://www.ncbi.nlm.nih.gov/pubmed/10468298 http://dx.doi.org/10.1038/sj.bjc.6690599 |
Ejemplares similares
-
Concurrent Hypofractionated Radiotherapy and 5-Fluorouracil for Advanced Sarcomas of the Bone
por: Zambatis, Charalambos, et al.
Publicado: (1998) -
Concurrent administration of Docetaxel and Stealth® liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection
por: Koukourakis, M I, et al.
Publicado: (2002) -
Radical flanks of social movements can increase support for moderate factions
por: Simpson, Brent, et al.
Publicado: (2022) -
Concurrent chemoradiotherapy with conventional fractionated radiotherapy and low-dose daily cisplatin plus weekly docetaxel for T2N0 glottic cancer
por: Saitoh, Jun-ichi, et al.
Publicado: (2017) -
Impact of concurrent chemotherapy on definitive radiotherapy for women with FIGO IIIb cervical cancer
por: Kuroda, Yuuki, et al.
Publicado: (2012)